Ibritumomab tiuxetan

Ibritumomab tiuxetan
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD20
Clinical data
Trade names	Zevalin
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US FDA: Ibritumomab;
Routes of; administration	intravenous
ATC code	V10XX02 (WHO) (90Y);
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	206181-63-7 ;
DrugBank	DB00078 ;
ChemSpider	none;
UNII	4Q52C550XK;
ChEMBL	ChEMBL1201606 ;
	(what is this?) (verify)

Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.